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ABSTRACT
Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by 
inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance 
is, however, a major problem. Determinants of rituximab sensitivity are not fully 
understood, but effect of rituximab are enhanced by antagonizing cell surface receptor 
CXCR4. In a two-step strategy, we tested the hypothesis that prognostic value of 
CXCR4 in DLBCL relates to rituximab treatment, due to a hampering effect of CXCR4 on 
the response of DLBCL cells to rituximab. First, by investigating the prognostic impact 
of CXCR4 mRNA expression separately for CHOP (n=181) and R-CHOP (n=233) cohorts 
and, second, by assessing the interaction between CXCR4 and rituximab in DLBCL cell 
lines. High CXCR4 expression level was significantly associated with poor outcome 
only for R-CHOP-treated patients, independent of IPI score, CD20 expression, ABC/
GCB and B-cell-associated gene signature (BAGS) classifications. s. For responsive 
cell lines, inverse correlation was observed between rituximab sensitivity and 
CXCR4 surface expression, rituximab induced upregulation of surface-expressed 
CXCR4, and growth-inhibitory effect of rituximab increased by plerixafor, supporting 
negative impact of CXCR4 on rituximab function. In conclusion, CXCR4 is a promising 
independent prognostic marker for R-CHOP-treated DLBCL patients, possibly due to 
inverse correlation between CXCR4 expression and rituximab sensitivity.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most 
common type of B-cell-derived non-Hodgkin lymphoma 
[1], with a varying response and long-term outcome 
following therapy. Addition of the anti-CD20 monoclonal 
antibody rituximab (R) to the cyclophosphamide, 
hydroxydaunorubicin, oncovin, and prednisone (CHOP) 
treatment regimen has improved survival outcome of 
DLBCL patients significantly [2]. However, refractory 
and recurrent disease are major clinical problems due to 
drug-specific molecular resistance in this heterogeneous 
www.oncotarget.com                                           Oncotarget, 2019, Vol. 10, (No. 7), pp: 717-731
           Research Paper
Oncotarget718www.oncotarget.com
disease, and patients with early relapse after rituximab-
containing first-line therapy have a poor prognosis [3]. 
Several mechanisms are involved in rituximab-induced 
depletion of B-cells including induction of apoptosis by 
direct signaling, antibody-dependent cellular cytotoxicity, 
and complement-dependent cytotoxicity [4, 5]. The 
precise mechanisms of action of rituximab and their 
relative contribution in patients is not fully understood, 
and determinants of rituximab sensitivity/resistance in the 
treatment of DLBCL remain unclear.
DLBCL is a very heterogeneous disease. Gene 
expression profiling studies have reported the presence 
of at least two histologically indistinguishable molecular 
subclasses of DLBCL: the germinal center B-cell-like 
(GCB) subclass, derived from germinal center cells, 
and the activated B-cell-like (ABC) subclass, whose 
expression pattern resembles that of B-cells committed 
to plasmacytic differentiation [6, 7]. The two molecular 
subclasses differ in clinical presentation, drug response, 
genetic aberrations, and gene expression [6, 8–10]. 
In an approach to extend this current cell-of-origin 
classification, we recently generated a refined DLBCL 
classification strategy based on more diverse subset-
specific B-cell-associated gene signatures (BAGS) 
from the normal B-cell hierarchy, by combining 
fluorescence-activated cell sorting and gene expression 
profiling of normal human tonsil B-cells, i.e. naïve 
B-cells, centrocytes, centroblasts, memory B-cells, 
and plasmablasts [11]. Importantly, BAGS subtyping 
showed prognostic impact independent of ABC/GCB 
classification and the International Prognostic Index 
(IPI) scoring system, the clinical tool used to evaluate 
the prognosis of DLBCL patients. Notably, within GCB-
DLBCL, superior prognosis was observed for the cohort 
classified as centrocyte subtype (CC) compared to 
centroblast subtype (CB). Interestingly, sorting of normal 
tonsil centrocytes and centroblasts for the generation 
of BAGS was based on differential surface expression 
of chemokine (C-X-C motif) receptor 4 (CXCR4), 
with centroblasts displaying higher expression than 
centrocytes [11].
CXCR4 is a G-protein-coupled chemokine receptor 
expressed on the surface of the majority of hematopoietic 
cells [12], whereas its ligand chemokine (C-X-C motif) 
ligand 12 (CXCL12) is normally produced by stromal 
cells of lymph nodes, liver, and bone marrow [13, 14]. 
CXCR4 and CXCL12 play a fundamental role in B-cell 
development, particularly in establishing the complex 
germinal center architecture of secondary lymphoid 
organs [15–17]. However, the CXCL12-CXCR4 axis 
has been linked to tumor proliferation [18], metastasis 
[13], and stroma-induced protection from anti-cancer 
treatment [19–21]; and CXCR4 expression has been 
associated with poor prognosis [22–24]. In Burkitt 
lymphoma [19, 20, 25] and chronic lymphocytic 
leukemia (CLL) [20, 21], the effect of rituximab was 
enhanced when antagonizing CXCR4 and, recently, 
we reported a synergistic effect when administering 
the CXCR4 antagonist plerixafor concomitantly with 
rituximab to DLBCL cells in vitro [26]. The association 
between CXCR4 expression level and rituximab-specific 
response has, however, not been thoroughly elucidated 
in DLBCL.
Here, we tested the hypothesis that the prognostic 
value of CXCR4 in DLBCL relates to rituximab treatment, 
due to a hampering effect of CXCR4 on the response 
of DLBCL cells to rituximab. Complement-dependent 
cytotoxicity is the mechanism in focus in this study 
since complement has been reported as essential to the 
therapeutic activity of rituximab in murine lymphoma 
models [27, 28] and since disruption of CLL-stromal 
cell interaction by CXCR4 antagonism in vitro was 
demonstrated to increase the efficacy of rituximab-induced 
complement-dependent cytotoxicity, whereas this was 
not the case for rituximab-induced antibody-dependent 
cellular cytotoxicity [21].
RESULTS
CXCR4 expression is an IPI score, ABC/GCB 
subclass, and CD20 expression-independent 
prognostic marker for R-CHOP-treated DLBCL 
patients
To investigate the prognostic value of CXCR4, 
dichotomized CXCR4 mRNA expression was analyzed 
for association to overall survival (OS), in the LLMPP 
(Lymphoma/Leukemia Molecular Profiling Project) 
cohort of 414 de novo diagnosed DLBCL patients. A 
strong association between CXCR4 mRNA expression 
level and 5-year OS was observed for the R-CHOP-
treated DLBCL patient cohort (n=233) but not for 
the CHOP-treated cohort (n=181), with high CXCR4 
expression characterizing poor outcome (Figure 1A-
1B). These observations are in agreement with simple 
Cox’s proportional hazards regression analyses using 
CXCR4 mRNA expression as a continuous variable 
(Table 1). When performing multiple Cox’s proportional 
hazards regression analysis, independent variables 
were only entered into the model if significant results 
were obtained at the 5% level when performing simple 
Cox’s proportional hazards regression analyses. Thus, 
multiple Cox’s proportional hazards regression for the 
R-CHOP-treated cohort revealed that the prognostic 
value of CXCR4 was independent of the already well-
established IPI scoring system (Table 1A) and ABC/GCB 
classification (Table 1B). Since rituximab is an anti-CD20 
antibody, it is of particular interest that the prognostic 
value was also independent of CD20 expression level 
(Table 1C). Thus, distinct pathogenetic and prognostic 
knowledge not already explained by the IPI, ABC/GCB 
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classification or CD20 expression levels could be captured 
by the CXCR4 expression levels.
CXCR4 expression is a BAGS-defined CC/CB 
subtype-independent prognostic marker for 
R-CHOP-treated GCB-DLBCL patients
When evaluating the prognostic impact of BAGS 
classification separately for ABC and GCB subclasses in a 
meta-analysis combining information on R-CHOP-treated 
patients from three individual clinical cohorts (including 
LLMPP), prognostic stratification was only observed 
within the GCB cohort, with inferior prognosis for the 
BAGS-defined CB subtype cohort compared to the CC-
classified cohort [11].
Here, we wanted to decipher the role of CXCR4 
expression in this significant difference in outcome. We 
found that when survival analysis was restricted to the 
Figure 1: Prognostic value of CXCR4 expression and BAGS-defined subtypes displaying different levels of CXCR4 
expression. (A-B) Kaplan-Meier plots depicting 5-year OS for CHOP (n=181) and R-CHOP-treated (n=233) DLBCL patients stratified 
by CXCR4 expression level (217028_at), using the median as cut point. (C-D) Kaplan-Meier plots depicting 5-year OS for BAGS-defined 
CC and CB subtypes for CHOP (CC, n=33; CB, n=26) and R-CHOP-treated (CC, n=58; CB, n=25) GCB-DLBCL patients. For comparison 
of survival curves, the log-rank test was used. For hazard ratio (HR) estimation, a simple Cox’s proportional hazards regression model was 
used.
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Table 1: CXCR4 expression is an (A) IPI score, (B) ABC/GCB subclass, (C) CD20 expression, and (D) GCB-CC/CB 
subtype-independent prognostic marker for R-CHOP-treated DLBCL patients
A na no.
Simple Multiple
HR 95% CI P HR 95% CI P
CHOP CXCR4 157 77 1.26 0.88-1.80 0.20 - - -
IPI
0-1 62 16 1
2-3 82 50 3.10 1.76-5.44 8.79E-05 - - -
4-5 13 11 6.45 2.98-13.95 2.18E-06 - - -
R-CHOP CXCR4 164 43 1.77 1.04-3.02 0.036 1.77 1.04-3.00 0.035
IPI
0-1 70 9 1 1
2-3 73 22 2.58 1.19-5.61 0.017 2.69 1.24-5.85 0.013
4-5 21 12 6.73 2.81-16.14 1.93E-05 6.65 2.78-15.93 2.12E-05
B n no.
Simple Multiple
HR 95% CI P HR 95% CI P
CHOP CXCR4 181 93 1.35 0.96-1.89 0.080 - - -
Subclass
ABC 74 49 1
GCB 76 28 0.42 0.26-0.66 0.00023 - - -
UC 31 16 0.72 0.41-1.27 0.26 - - -
R-CHOP CXCR4 233 60 1.72 1.11-2.66 0.014 1.54 1.01-2.32 0.042
Subclass
ABC 93 39 1 1
GCB 107 16 0.30 0.17-0.53 4.42E-05 0.32 0.18-0.57 0.00014
UC 33 5 0.29 0.11-0.73 0.0084 0.28 0.11-0.72 0.0078
C n no.
Simple Multiple
HR 95% CI P HR 95% CI P
CHOP Entire cohort
CXCR4 181 93 1.35 0.96-1.89 0.080 - - -
CD20 181 93 0.88 0.72-1.06 0.18
GCB 
(CC+CB)b
CXCR4 59 19 1.24 0.53-2.88 0.62 - - -
CD20 59 19 0.95 0.54-1.67 0.85 - - -
R-CHOP Entire cohort
CXCR4 233 60 1.72 1.11-2.66 0.014 1.71 1.12-2.62 0.014
CD20 233 60 0.77 0.65-0.91 0.0024 0.75 0.62-0.90 0.0022
(Continued )
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cohort of LLMPP patients classified as GCB subclass 
and CC (GCB-CC) or CB (GCB-CB) subtype, the CB 
subtype was still associated with an inferior 5-year OS 
compared to the CC subtype; regardless of treatment 
strategy (Figure 1C-1D). The GCB-CB subtype does not 
seem to benefit much from addition of rituximab since the 
3-5-year OS was around 55% for both treatment cohorts, 
whereas 5-year OS for the GCB-CC cohort increased from 
approximately 80% to 90% upon addition of rituximab 
to the treatment regimen. BAGS-defined CC and CB 
subtypes carry reminiscences of normal centrocyte and 
centroblast transcriptomic profiles, respectively, and since 
CXCR4 expression level is diminished in normal tonsil 
centrocytes compared to centroblasts [11], we speculated 
that CXCR4 may hamper the effect of rituximab in the 
GCB-CB subtype. To determine if this distinct difference 
in CXCR4 expression level is sustained in patients, we 
assessed the CXCR4 expression level in patient samples 
and found that the GCB-CB-assigned patient cohort 
had a higher expression level of CXCR4 compared to 
the GCB-CC cohort, whether treated with CHOP or 
R-CHOP (Figure 2A-2B). To test if CXCR4 expression 
level is a surrogate marker for the difference in outcome 
observed between GCB-CC and GCB-CB-assigned patient 
cohorts, we used multiple Cox’s proportional hazards 
regression analysis. We observed CXCR4 expression 
to be an independent prognostic marker of 5-year OS 
following R-CHOP therapy (Table 1D); thus adding 
prognostic information independent of the BAGS-defined 
classification. Of notice, the cohort of R-CHOP-treated 
patients assigned as GCB-CC displayed a significantly 
higher CD20 expression level than the GCB-CB cohort 
(mean difference, 0.59; 95% CI, 0.055-1.1; P=0.032); 
a difference which was not observed for CHOP-treated 
patients (mean difference, -0.13; 95% CI, -0.57-0.31; 
P=0.56) (Supplementary Figure 1A-1B). When restricting 
the Cox’s proportional hazards regression analysis to the 
GCB-CC/GCB-CB cohort, CXCR4 expression remained 
a prognostic factor for R-CHOP-treated patients, whereas 
CD20 expression level was no longer of significance 
(Table 1C).
CXCR4 surface expression level is inversely 
correlated to the degree of rituximab sensitivity 
for responsive DLBCL cell lines
To test if the prognostic significance of CXCR4 
mRNA expression can be supported by experimental 
C n no.
Simple Multiple
HR 95% CI P HR 95% CI P
GCB 
(CC+CB)b
CXCR4 83 14 5.03 1.93-13.09 0.00093 - - -
CD20 83 14 0.86 0.49-1.50 0.59 - - -
D nb no.
Simple Multiple
HR 95% CI P HR 95% CI P
CHOP CXCR4 59 19 1.24 0.53-2.88 0.62 - - -
Subtype
GCB-CC 33 6 1
GCB-CB 26 13 3.39 1.29-8.94 0.013 - - -
R-CHOP CXCR4 83 14 5.03 1.93-13.09 0.00093 4.57 1.71-12.18 0.0024
Subtype
GCB-CC 58 5 1 1
GCB-CB 25 9 5.40 1.81-16.16 0.0026 4.49 1.48-13.67 0.0081
Connection of CXCR4 (217028_at) expression level to 5-year OS, analyzed using simple and multiple Cox’s proportional 
hazards regression models.
a IPI score information was not available for all patients, thus cohort sizes are reduced in this setting; b The cohort is 
restricted to patients classified as GCB-CC or GCB-CB; n, number of samples; no., number of events; HR, hazard ratio; 
CI, confidence interval; UC, unclassified; -, value is not available since significant results at the 5% level were obtained for 
only one of the independent variables when performing simple Cox’s proportional hazards regression analysis.
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analyses at the protein level, the relationship between 
CXCR4 mRNA and CXCR4 surface expression level 
was assessed for fourteen drug-naïve human DLBCL cell 
lines. CXCR4 surface expression was analyzed by flow 
cytometry and correlated to CXCR4 gene expression data, 
documenting a positive correlation (rho=0.92, P<2.2e-16) 
(Supplementary Figure 2A).
The linear relationship between CXCR4 surface 
expression and the degree of rituximab-induced response 
was evaluated for the same panel of cell lines. To divide 
these cell lines into rituximab response groups, systematic 
dose-response screens were performed (Figure 3A-3B), 
using MTS-based determination of growth inhibition to 
measure rituximab-induced effect after 48 hours of drug 
exposure, applying sixteen decreasing concentrations of 
rituximab (133.33 μg/ml – 4.07×10-3 μg/ml). Two dose-
response screens were performed in parallel; one with 
human serum included as a source of complement (Figure 
3A) and one in which the human serum had been heat-
inactivated (Figure 3B), illustrating that the drug effect 
was far more pronounced when complement-dependent 
cytotoxicity could occur. AUC0
G  (area under dose-
response curve obtained by the G-model [29])-values were 
used to assess the degree of rituximab-induced response 
in the human serum setting (Figure 3C), with a high value 
corresponding to a low sensitivity towards rituximab and 
vice versa. Based on these AUCG0 -values, cell lines were 
divided into tertiles and classified as either rituximab 
sensitive, intermediate sensitive, or resistant (Figure 3C). 
For sensitive and intermediate sensitive cell lines, the 
degree of human serum-dependent rituximab sensitivity 
was inversely correlated to the level of surface-expressed 
CXCR4, whereas this was not the case for resistant cell 
lines (Figure 3D). Notably, even though the resistant 
cell lines had comparable AUCG0 -values, these cell 
lines displayed very different CXCR4 surface expression 
levels. Thus, an increase in CXCR4 surface expression 
level coincided with decreased rituximab sensitivity for 
the sensitive and intermediate sensitive cell lines, whereas 
CXCR4 did not impact the sensitivity status of resistant 
cell lines. Since rituximab targets the CD20 cell surface 
receptor, it is relevant to notice that CXCR4 and CD20 
surface expression levels did not correlate significantly 
(sensitive: r=-0.75, P=0.14; intermediate sensitive: r=0.65, 
P=0.35; resistant: r=-0.43, P=0.48) (Supplementary 
Figure 2B).
Rituximab induces upregulation of CXCR4 on 
the surface of responsive cells in an inactivated 
human serum setting
To assess the impact of rituximab on the level of 
surface-expressed CXCR4, four DLBCL cell lines were 
exposed to two doses of rituximab (1.04 μg/ml, 8.33 μg/ml) 
for 24 and 48 hours before flow cytometry-based analysis 
was conducted (Figure 4). Again, parallel experiments 
were performed (human serum vs. heat-inactivated human 
serum). In the rituximab sensitive cell lines SU-DHL-4 
(Figure 4A) and RIVA (Figure 4B) and the intermediate 
sensitive cell line FARAGE (Figure 4C), CXCR4 surface 
Figure 2: CXCR4 expression level (217028_at) in BAGS-defined CC and CB subtypes, for GCB-DLBCL patients. 
Individual analysis of the LLMPP (A) CHOP treated cohort (GCB-CC, n=33; GCB-CB, n=26) and (B) R-CHOP treated cohort (GCB-CC, 
n=58; GCB-CB, n=25) using Welsch’s t-test to test for statistical significance, presenting mean differences with 95% CIs.
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expression level was increased following rituximab 
exposure, when supplemented with heat-inactivated 
human serum. In contrast, no increase in CXCR4 surface 
expression level was observed when rituximab was applied 
together with human serum. For the resistant cell line OCI-
Ly8 (Figure 4D), the impact on expression level was far 
less than for the responsive cell lines and the effect was not 
affected by human serum status.
Figure 3: CXCR4 surface expression level is inversely correlated to the degree of rituximab sensitivity for responsive 
DLBCL cell lines. (A-B) Systematic rituximab dose-response screens of fourteen human DLBCL cell lines and the CD20-negative 
multiple myeloma cell line RPMI-8226 (negative control) in a human serum (HS) and heat-inactivated human serum (inHS) setting. Curves 
are depicted as the average of at least three independent experiments per cell line. (C) Box plots illustrating rituximab sensitivity ranking of 
the cell lines by AUCG0 -values, based on the curves from (A). (D) Linear relationship between drug-naïve CXCR4 surface expression level 
and degree of rituximab sensitivity (AUCG0 -values from (C)) for different rituximab response groups, assessed by Pearson’s correlation. 
CXCR4 surface expression levels are reported as fold changes in median fluorescence intensity (MFI) relative to an unstained control and 
plotted as the mean of three independent experiments per cell line. Each circle represents a distinct cell line. 1, SU-DHL-4; 2, OCI-Ly7; 3, 
NU-DUL-1; 4, SU-DHL-5; 5, RIVA; 6, NU-DHL-1; 7, DB; 8, FARAGE; 9, U2932; 10, OCI-Ly19; 11, OCI-Ly8; 12, OCI-Ly3; 13, HBL-1; 
14, SU-DHL-8.
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Antagonizing CXCR4 on the surface of 
responsive cells increases rituximab efficacy
The inhibiting effect of CXCR4 on rituximab-
induced response in the human serum setting was 
investigated by combining rituximab treatment with the 
CXCR4 antagonist plerixafor. RIVA and OCI-Ly8 have 
comparable CXCR4 surface expression levels (Figure 
3D). However, RIVA is sensitive to rituximab whereas 
OCI-Ly8 is resistant (Figure 3C). Both cell lines were 
incubated with rituximab (10 μg/ml), plerixafor (500 
μM), or rituximab in combination with plerixafor, 
and the number of living cells/ml was determined 
by automated cell counting at 24, 48, and 72 hours 
post-treatment (Figure 5). As expected, we observed 
rituximab monotherapy to result in a significant decrease 
in the number of living cells for RIVA (Figure 5A), 
whereas this was not the case for OCI-Ly8 (Figure 
5B). Single agent treatment with plerixafor did not 
considerably affect the number of living cells, in any 
of the cell lines. Notably, exposing RIVA cells to a 
combination of the two drugs increased the effect of 
rituximab remarkably, whereas only a relatively small 
decrease in the number of living cells was observed for 
OCI-Ly8 after 48 hours.
DISCUSSION
In a two-step strategy, we have tested the hypothesis 
that the prognostic value of CXCR4 in DLBCL relates to 
rituximab treatment, due to a hampering effect of CXCR4 
on the response of DLBCL cells to rituximab. First, by 
investigating the prognostic impact of CXCR4 expression 
separately for CHOP and R-CHOP cohorts of a clinical 
DLBCL dataset and, second, by studying the association 
between CXCR4 surface expression and rituximab 
sensitivity in a panel of up to fourteen human DLBCL cell 
lines.
We determined CXCR4 expression to be significantly 
associated with outcome in a cohort of 233 R-CHOP-
treated DLBCL patients, demonstrating a decreased 
5-year OS for patients with high CXCR4 expression 
(Figure 1). Several immunohistochemistry-based studies 
are in agreement [22, 23, 24, 30]. More specifically, high 
CXCR4 membrane expression was recently associated 
with disease progression in a small cohort of primary 
Figure 4: Rituximab induces upregulation of CXCR4 on the surface of responsive cells in an inactivated human 
serum setting. The bar charts show rituximab-induced effect on the CXCR4 surface expression level of (A-B) rituximab sensitive, (C) 
intermediate sensitive, and (D) resistant DLBCL cell lines, in a human serum (HS) and heat-inactivated human serum (inHS) setting. 
CXCR4 surface expression levels are reported as fold changes in MFI relative to an unstained control and plotted as the mean of two 
technical replicates for SU-DHL-4 and three technical replicates for the remaining cell lines. Error bars represent standard deviations. C0, 
saline; C9, 1.04 μg/ml; C12, 8.33 μg/ml; Unstained, unstained control.
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testicular DLBCL patients [23], with poor survival in a 
cohort of 94 DLBCL patients treated with rituximab-
containing regimens (92.5% R-CHOP) [24], and with 
a tendency towards worse outcome in a cohort of 70 
R-CHOP-treated DLBCL patients of which only 8 were 
classified as CXCR4-negative [30]. Additionally, in 
a large training/validation cohort of 468/275 de novo 
DLBCL patients, high CXCR4 expression was associated 
with significantly poorer OS in the overall cohort of 
R-CHOP-treated DLBCL patients, independent of several 
pathological and clinical parameters [22]. In our study, 
multiple Cox’s proportional hazards regression analyses 
revealed that CXCR4 expression shows prognostic impact 
for R-CHOP-treated DLBCL patients, independent of IPI 
score, ABC/GCB classification, and CD20 expression. 
Furthermore, the prognostic impact was independent 
of our recently reported BAGS-defined CC and CB 
subtype classification, for GCB-classified patients. These 
results indicate that distinct pathogenetic and prognostic 
knowledge not already explained by these prognostic 
parameters can be captured by CXCR4 expression level. 
Combined, this illustrates that CXCR4 expression holds 
potential as a very useful marker of outcome for R-CHOP-
treated DLBCL patientsat the mRNA level. Notably, the 
prognostic impact of CXCR4 expression was enhanced 
when rituximab was included in the chemotherapy 
regimen, in a manner indicating that the effect of rituximab 
may be negatively affected by CXCR4. Accordingly, our 
in vitro studies of rituximab-induced response imply that 
CXCR4 surface expression level correlates inversely 
with the degree of rituximab response for sensitive and 
intermediate sensitive, however not for resistant, DLBCL 
cell lines (Figure 3D). This suggests that CXCR4 is a 
determinant of rituximab sensitivity degree but is not a 
controller of intrinsic rituximab resistance mechanisms. 
Since CXCR4 and CD20 surface expression levels did 
not correlate significantly, our observations do not merely 
reflect a difference in CD20 expression level, the target of 
rituximab.
In our BAGS classification system, CXCR4 surface 
expression was used as a marker for distinguishing 
between normal human tonsil centrocytes and centroblasts, 
with centroblasts displaying higher CXCR4 expression 
than centrocytes; a pattern also evident at the mRNA 
expression level [11]. The BAGS-defined CC/CB subtypes 
are reminiscent of normal centrocytes and centroblasts, 
respectively, with the GCB-CB-assigned patient cohort 
displaying higher CXCR4 expression than the GCB-CC 
cohort. Importantly, the GCB-CC cohort had a superior 
5-year OS compared to the GCB-CB cohort, and the 
GCB-CC subtype seemed to benefit from addition of 
rituximab to the treatment regimen, whereas the GCB-
CB subtype did not. This suggests that the improved 
outcome observed for the GCB-CC cohort in the R-CHOP 
setting may result from a rituximab-dependent mechanism 
which is hampered by CXCR4 in the GCB-CB subtype. 
Thus, the difference in CXCR4 expression level between 
GCB-CC and GCB-CB patient cohorts could be an 
explanatory factor for the difference in outcome. Notably, 
CXCR4 expression was of significant prognostic value 
for R-CHOP-treated patients, independent of GCB-CC/
GCB-CB classification. Since rituximab is an anti-CD20 
antibody, it is relevant to notice that the GCB-CC-assigned 
R-CHOP-treated patient cohort displayed a higher CD20 
Figure 5: Antagonizing CXCR4 on the surface of responsive cells increases rituximab efficacy. The impact of CXCR4 
antagonism (plerixafor) on the rituximab-induced response of (A) rituximab sensitive and (B) resistant DLBCL cell lines. Data are presented 
as the mean number of living cells/ml of two independent experiments per cell line, with error bars representing standard error of the mean. 
Linear mixed-effects models were used to assess statistical significance between treatment groups, using untreated control as reference for 
rituximab and plerixafor monotherapy, and rituximab monotherapy as reference for combination treatment. Untreated, untreated control; 
RTX, rituximab monotherapy; PLX, plerixafor monotherapy; RTX+PLX, combination treatment; ##/**, P<0.01; ###/***, P<0.001; n.s., no 
significant difference.
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expression level than the GCB-CB cohort. Thus, in 
addition to the lower CXCR4 expression level, the higher 
CD20 expression level observed for this cohort could be 
an explanatory factor for the superior prognosis observed 
for the GCB-CC cohort. In the overall LLMPP R-CHOP 
cohort, CD20 and CXCR4 expression showed significant 
and independent prognostic impact. In the GCB-CC/
GCB-CB-restricted R-CHOP cohort, CXCR4 expression 
remained of significant value whereas CD20 expression 
did not. Therefore, we propose that CXCR4 expression 
is a superior prognostic marker in this defined cohort of 
DLBCL patients compared to CD20 expression. However, 
the reduction in cohort size from 233 to 83 patients might 
have influenced these results.
In a cohort of 20 non-Hodgkin lymphoma patients, 
a significantly better prognosis and favorable treatment 
response was observed for patients experiencing a 
post-treatment decrease in CXCR4 expression in the 
bone marrow [31]. In the light of this finding, it is of 
particular interest that we demonstrated rituximab to 
induce upregulation of CXCR4 expression on the surface 
of responsive cells; especially when combined with 
our observation that their level of surface-expressed 
CXCR4 correlated inversely with the degree of 
rituximab response. Hence, exposure to rituximab might 
render responsive cells more resistant to rituximab as 
a consequence of a rituximab-induced upregulation of 
surface-expressed CXCR4; a mechanism not observed 
for resistant cells. However, exposure to different 
physiologic conditions might be required for this to 
occur, as rituximab-induced CXCR4 upregulation was 
observed only in the presence of inactivated human 
serum, whereas correlation of CXCR4 level and rituximab 
response was demonstrated in a human serum setting. A 
physiologic in vivo evaluation of this proposed negative 
feedback mechanism is, therefore, warranted. Treatment-
induced upregulation of CXCR4 has been reported in 
other studies. In rectal carcinoma cells, upregulation of 
CXCR4 was observed following anti-VEGF antibody 
treatment [32] and, recently, rituximab was shown to 
induce upregulation in Burkitt lymphoma cell lines and 
primary DLBCL cells [19]. Metastasis and subsequent 
acquired rituximab resistance due to stroma-induced 
protection might be another implication of rituximab-
induced CXCR4 upregulation. CXCL12 is normally 
produced by stromal cells of lymph nodes, liver, and 
bone marrow [13, 14], creating a CXCL12 concentration 
gradient that promotes migration of CXCR4-positive 
normal and malignant hematopoietic cells to these areas. 
Microenvironment-induced inhibition of drug efficacy 
has been described in CLL [21] and Burkitt lymphoma 
[19, 20], where host stromal tissue was shown to protect 
against rituximab-induced cytotoxicity. Antagonizing 
CXCR4 abrogated this protective effect, emphasizing the 
role of CXCR4 in microenvironment-induced rituximab 
resistance.
CXCR4 surface expression might more directly 
counteract the effect of rituximab. By comparing the 
effect of rituximab in the presence and absence of the 
CXCR4 antagonist plerixafor, we found that the in vitro 
effect of rituximab was enhanced when CXCR4 was 
antagonized; supporting that CXCR4 impairs the function 
of rituximab. We observed that cells with comparable 
CXCR4 surface expression levels but different degrees of 
sensitivity towards rituximab exhibited different responses 
to combination treatment, with the effect being remarkably 
more pronounced for responsive cells, further implying 
that CXCR4 is involved in rituximab sensitivity but not 
in intrinsic resistance mechanisms. In agreement with our 
observations, inhibition of the CXCL12-CXCR4 axis by 
CXCR4 antagonists improved the efficacy of rituximab 
in Burkitt lymphoma [19, 20, 25] and CLL [20, 21] and, 
very recently, we reported that synergistic effect can be 
assumed when concomitantly administering rituximab and 
plerixafor to DLBCL cells, with combination treatment 
effect depending on factors such as drug concentration and 
administration sequence [26]. Upon binding of CXCL12 
to CXCR4, divergent cell signaling pathways are triggered 
[33], leading to activated PI3K/Akt and MAPK pathways 
[34, 35]. Interestingly, rituximab efficacy has been shown 
to depend on the degree of PI3K/Akt and MAPK signaling 
deregulation [36–38]. Thus, CXCR4-induced deregulation 
of these pathways might be an explanatory factor for its 
hampering effect on rituximab response observed for 
rituximab-responsive DLBCL cells.
Although in vitro experiments are useful for studying 
isolated events in a controlled and very reproducible 
setting, we acknowledge that in vitro experiments cannot 
capture the complexity of the biological system. Especially 
factors such as interaction between different mechanisms, 
exact microenvironmental conditions, and system 
dynamics are difficult to model. Thus, although disruption 
of tumor-stromal cell interaction by CXCR4 antagonism 
did not increase the efficacy of rituximab-induced 
antibody-dependent cellular cytotoxicity in vitro [21], this 
might be the case in vivo. In support of this, neutrophil 
depletion was demonstrated to abolish plerixafor-induced 
enhancement of rituximab efficacy in a murine lymphoma 
model, probably due to the ability of plerixafor to not only 
disrupt the interaction between tumor and stromal cells but 
also to mobilize effector cells to the blood [25]. Therefore, 
it would be interesting to extend the findings of this study 
by investigating the impact of CXCR4 on mechanisms 
involved in rituximab-induced depletion of tumor cells in 
an in vivo model system.
In summary, high CXCR4 expression was 
significantly associated with poor prognosis for DLBCL 
patients when rituximab was included in the CHOP 
treatment regimen. Importantly, this prognostic value 
of CXCR4 was independent of IPI score, ABC/GCB 
classification, CD20 expression and, for GCB-DLBCL 
patients, the CC and CB subtypes of our recently 
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defined BAGS classification system. Furthermore, 
rituximab-induced response was hampered by CXCR4 
on the surface of DLBCL cells, with inverse correlation 
between CXCR4 surface expression level and degree of 
rituximab sensitivity, for rituximab responsive but not 
for resistant cell lines; implying that CXCR4 plays a role 
in rituximab sensitivity but not in intrinsic resistance. 
Combined, this suggests that CXCR4 holds promise as 
an independent prognostic marker for R-CHOP-treated 
DLBCL patients due to a hampering effect of CXCR4 
Table 2: Cell line specifications
Cell Line Cell Type Supplier/
Purchase 
Information
Culture Mediuma Seeding 
Concentration 
(×106 cells/ml)
Rituximab Responseb
SU-DHL-4 DLBCL DSMZ Acc. 495 RPMI 1640 + 10% FBS 0.3 Sensitive
OCI-Ly7 DLBCL 1 RPMI 1640 + 10% FBS 0.3 Sensitive
NU-DUL-1 DLBCL DSMZ Acc. 579 RPMI 1640 + 15% FBS 0.3 Sensitive
SU-DHL-5 DLBCL DSMZ Acc. 571 RPMI 1640 + 20% FBS 0.3 Sensitive
RIVA DLBCL 1 RPMI 1640 + 10% FBS 0.3 Sensitive
NU-DHL-1 DLBCL DSMZ Acc. 583 RPMI 1640 + 10% FBS 0.15 Intermediate
DB DLBCL DSMZ Acc. 539 RPMI 1640 + 20% FBS 0.15 Intermediate
FARAGE DLBCL 1 RPMI 1640 +10% FBS 0.3 Intermediate
U2932 DLBCL 1 RPMI 1640 + 10% FBS 0.5 Intermediate
OCI-Ly19 DLBCL 1 RPMI 1640 + 10% FBS 0.3 Resistant
OCI-Ly8 DLBCL 2 RPMI 1640 + 10% FBS 0.3 Resistant
OCI-Ly3 DLBCL 1
IMDM + 20% 
inHS + 55μM 
2-mercaptoethanol
0.15 Resistant
HBL-1 DLBCL 1 RPMI 1640 + 10% FBS 0.3 Resistant
SU-DHL-8 DLBCL 1
RPMI 1640 + 
10% FBS + 2mM 
L-glutamin
0.3 Resistant
RPMI-8226 Multiple myeloma DSMZ Acc. 402
RPMI 1640 + 10% 
FBS 0.15 Negative control
a All culture media were supplemented with 1% penicillin-streptomycin; b Cell lines are ranked as rituximab sensitive, 
intermediate sensitive, or resistant according to their AUCG0 -value in the human serum setting; 1, Kind gift from Associate 
Professor Jose A. Martinez-Climent, MD, PhD, University of Navarra, Pamplona, Spain; 2, Kind gift from Professor Hans 
Messner, MD, PhD, University of Toronto, Toronto, Canada; FBS, fetal bovine serum; inHS, heat-inactivated human serum; 
DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH; RPMI, Roswell Park Memorial Institute; 
IMDM, Iscove's Modified Dulbecco's Medium.
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on rituximab-induced response. To further establish this 
concept, it would be particularly interesting to validate 
our findings in a prospective study and to explore the 
biological mechanisms that underlie the proposed inverse 
relationship between CXCR4 expression and rituximab 
sensitivity.
MATERIALS AND METHODS
Clinical dataset
For clinical data analysis, gene expression data 
from Affymetrix GeneChip Human Genome U133 
Plus 2.0 Array-based analyses of 414 DLBCL patient 
samples collected prior to treatment initiation (CHOP, 
n=181; R-CHOP, n=233) were used. The dataset is 
deposited in the Gene Expression Omnibus repository 
under accession number GSE10846 and is referred to as 
the LLMPP cohort. Information about IPI is available 
(CHOP, n=157; R-CHOP, n=164). Details can be found 
in Lenz et al. [10].
Proof of principle validation of microarray 
based CXCR4 expression by quantitative digital 
droplet PCR
To ensure that microarray based determination 
of CXCR4 expression is trustworthy we performed 
a small validation assessment on an in house cohort 
of 52 DLBCL de novo clinical diagnostic samples 
(GSE110376) for correlation of CXCR4 probe 217028_
at expression on GeneChip Human Genome U133 Plus 
2.0 and relative expression of CXCR4 determined 
by digital droplet PCR (TaqMan #Hs00237052_m1) 
(Supplementary Figure 3). Person correlation coefficient 
was 0.84 documenting a fair reproducibility across 
detection methods despite differences in time; e.g. 
microarrays were run in 2015 whereas ddPCR were 
performed in 2018 using remaining RNA aliquots stored 
at -80 °C and normalization procedures where RMA was 
used for microarrays vs usage of similar RNA-equivalent 
cDNA input in ddPCR normalized against mean of 
reference genes TBP and PPIA.
Human DLBCL cell lines
Fourteen human DLBCL-derived cell lines, i.e. 
SU-DHL-4, OCI-Ly7, NU-DUL-1, SU-DHL-5, RIVA, 
NU-DHL-1, DB, FARAGE, U2932, OCI-Ly19, OCI-
Ly8, OCI-Ly3, HBL-1, and SU-DHL-8, were included 
(Table 2). The CD20-negative multiple myeloma cell 
line, RPMI-8226, was included as negative control. 
Cells were maintained under appropriate culturing 
conditions, and their identity was validated regularly 
using the DNeasy Blood and Tissue Kit (Qiagen, 
Copenhagen, Denmark), the AmpFISTR® Identifiler® PCR 
Amplification Kit (Applied Biosystems, CA, USA), and 
capillary electrophoresis (Eurofins Medigenomix GmbH, 
Applied Genetics, Germany). A unique identification was 
generated by use of the Osiris program and the German 
Collection of Microorganisms and Cell Cultures (DSMZ) 
database (http://www.dsmz.de/services/services-human-
and-animal-cell-lines/online-str-analysis.html), checking 
the length of nine out of sixteen short tandem repeats. 
The EZ-PCR Mycoplasma Test Kit (Biological Industries, 
Beit HaEmek, Israel) was used to exclude mycoplasma-
induced changes. Whenever incubation details are not 
supplied, cells were incubated in a humidified atmosphere 
at 37°C, 5% CO2.
MTS-based dose-response screens
Systematic rituximab dose-response screens were 
performed for all cell lines. Cells were seeded in 96-well 
culture plates at concentrations ranging from 0.15-0.5×106 
cells/ml (Table 2) and incubated overnight before applying 
saline or sixteen decreasing concentrations of rituximab 
(MabThera®, Roche, Copenhagen, Denmark) in 2-fold 
dilutions from C16=133.33 μg/ml to C1=4.07×10-3 μg/
ml. After 30 minutes of incubation, 20% human serum 
(Pooled Human AB Serum, Novakemi AB, Handen, 
Sweden) or heat-inactivated human serum was added, 
to enable assessment of rituximab-induced complement-
dependent cytotoxicity [4]. Impact of rituximab was tested 
by determining the number of metabolically active cells, 
using an MTS-based colorimetric method. An MTS-
containing reagent (CellTiter 96 Aqueous One Solution 
Reagent, Promega, WI, USA) was added immediately 
and 48 hours after serum addition. Following incubation 
for exactly 2 hours, absorbance at 492 nM was measured 
using an Optima-Fluostar (BMG LABTECH, Ortenberg, 
Germany). Cell count estimates were obtained at 
approximately 1 and 49 hours since these time points 
represent the center of MTS exposure. Only non-border 
wells were used for subsequent analysis to avoid border 
effects. To achieve high reproducibility, technical 
triplicates were included, and the entire experiment was 
repeated at least thrice per cell line.
Flow cytometry
Drug-naïve CXCR4 surface expression was 
analyzed for all cell lines. Approximately 1×106 cells were 
suspended in 40 μl Stain Buffer (phosphate-buffered saline 
containing 2% fetal bovine serum), adding 10 μl PE-
conjugated anti-CXCR4 antibody (clone 12G5, Beckman 
Coulter, Copenhagen, Denmark). Following incubation 
(15 min, room temperature, in dark), cells were washed 
with 3 ml Stain Buffer before centrifugation (500×g, 5 
min, room temperature) and resuspension in 0.4 ml Stain 
Buffer. Three independent experiments were conducted 
per cell line.
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CXCR4 surface expression upon rituximab exposure 
was analyzed for SU-DHL-4, RIVA, FARAGE, and OCI-
Ly8. Cells were seeded (0.3×106 cells/ml) in 24-well 
culture plates and incubated overnight. After addition of 
saline or rituximab (C9=1.04 μg/ml, C12=8.33 μg/ml), 
cells were incubated for 30 minutes, after which either 
20% human serum or heat-inactivated human serum was 
added. Following incubation for 24 and 48 hours, cells 
were harvested, washed with 2 ml phosphate-buffered 
saline, resuspended in 80 μl Stain Buffer, and stained 
by adding 20 μl PE-conjugated anti-CXCR4 antibody 
(clone 12G5, Beckman Coulter, Copenhagen, Denmark). 
Following incubation (15 min, room temperature, in 
dark), cells were washed with 3 ml Stain Buffer before 
centrifugation (500×g, 5 min, room temperature) and 
resuspension in 0.25 ml Stain Buffer. At least two 
technical replicates were included.
For all experiments, unstained controls were 
included to detect auto-fluorescence, a BD FACSCanto™ 
II (BD Biosciences, Copenhagen, Denmark) flow 
cytometer was used for acquisition, and FlowJo Software 
(Tree Star Inc., OR) for data analysis.
Cell counting
Enumeration of living cells (RIVA, OCI-Ly8) 
was performed by automated cell counting. Cells were 
seeded (0.3×106 cells/ml) in 24-well culture plates and 
incubated overnight before drug/saline and 20% human 
serum was added. Rituximab (10 μg/mL) and plerixafor 
(500 μM) (InSolution™ CXCR4 Antagonist I, AMD3100, 
Merck Millipore, Copenhagen, Denmark) was added 
concomitantly or individually. Following 24, 48, and 
72 hours of drug exposure, cells were counted using a 
NucleoCounter® NC-200™ (ChemoMetec, Copenhagen, 
Denmark) automated cell counter. Three separate 
countings were performed per well, and experiments were 
repeated twice.
Statistical analysis
For survival analysis, the hybridization-specific 
CXCR4 probe set 217028_at was chosen for assessment 
of expression level, which was either included as a 
dichotomized (median split) or continuous variable. 
Survival analysis was performed using Kaplan-Meier 
analysis, log-rank test, and simple Cox’s proportional 
hazards regression analysis. Multiple Cox’s proportional 
hazards regression analysis was used to adjust for either 
IPI score, ABC/GCB subclass, CD20 expression, or 
BAGS-defined subtype [11]. To test for difference in 
mean expression level between subtypes, Welch’s t-test 
was used.
For rituximab dose-response screens, raw 
absorbance values were pre-processed using a previously 
described model-based procedure [29]. Dose-response 
curves and time-independent summary statistics (AUCG0
-values) were estimated using the G-model combined with 
an established statistical analysis workflow [29]. Pearson’s 
correlation coefficients were estimated to determine the 
strength of the linear relationship between expression 
levels and AUCG0 -values for each rituximab response 
group, whereas linear models which take grouping 
according to rituximab sensitivity into account were used 
for plotting lines of best fit, and linear mixed-effects 
models applied to evaluate the effect of treatment on the 
number of living cells, with experimental replicate as 
random effect.
Statistical analyses were performed using the 
statistical software R [39], and P<0.05 was considered 
statistically significant.
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